Genome-wide association studies have identified 108 schizophrenia risk loci, but biological mechanisms for individual loci are largely unknown. Using developmental, genetic and illness-based RNA sequencing expression analysis in human brain, we characterized the human brain transcriptome around these loci and found enrichment for developmentally regulated genes with novel examples of shifting isoform usage across pre-and postnatal life. We found widespread expression quantitative trait loci (eQTLs), including many with transcript specificity and previously unannotated sequence that were independently replicated. We leveraged this general eQTL database to show that 48.1% of risk variants for schizophrenia associate with nearby expression. We lastly found 237 genes significantly differentially expressed between patients and controls, which replicated in an independent dataset, implicated synaptic processes, and were strongly regulated in early development. These findings together offer genetics-and diagnosis-related targets for better modeling of schizophrenia risk. This resource is publicly available at http://eqtl.brainseq.org/phase1.
S chizophrenia is a prevalent neuropsychiatric disorder with a combination of genetic and environmental risk factors. Research over the last several decades has suggested that it is a neurodevelopmental disorder arising through altered connectivity and plasticity in relevant neural circuits. However, discovering the causative mechanisms of these putatively developmental deficits has been challenging 1 . The most credible evidence of etiologic mechanisms related to schizophrenia has come from a recent genome-wide association study (GWAS) in which over a hundred independent single nucleotide polymorphisms (SNPs) exhibited significant allele frequency differences between patients with schizophrenia and unaffected controls 2 . While these findings have identified regions in the genome harboring genetic risk variants, almost all of the associated SNPs are noncoding, located in intronic or intergenic sequence, which have been previously suggested to have some role in regulating expression 3 . However, the exact gene(s) and transcript(s) potentially regulated by risk-associated genetic variation are uncertain, as most of these genomic regions contain multiple genes. In principle, the effects of noncoding genetic variation, by whatever mechanisms (for example, promoter, enhancer, splicing, noncoding RNA, epigenetics), should be observed in the transcriptome. Therefore, to better understand how these regions of genetic risk and their underlying genotypes may confer risk of schizophrenia and to better characterize the molecular biology of the disease state, we performed RNA sequencing (RNA-seq) on tissue from 495 individuals with ages across the lifespan, including 175 patients with schizophrenia.
Here we identify expression associations with genetic risk and with illness state and explore developmentally regulated features, including a subset of genes with previously uncharacterized isoform shifts in expression patterns across the fetal-postnatal developmental transition. We further identify many more eQTLs in schizophrenia risk regions than previously observed by surveying the full spectrum of expression features to generate potential molecular mechanisms underlying genetic risk. We also explore differential gene expression associated with the state of illness in a comparison of the postmortem brains of patients with schizophrenia with non-psychiatric controls. By incorporating a recently described experiment-based algorithm to account for RNA quality differences that have not been adequately controlled in earlier studies, we report a high degree of replication across independent case-control gene expression datasets 4, 5 . By combining genetic risk at the population-level with eQTLs and case-control differences, we identify putative human frontal cortex mechanisms contributing to risk for schizophrenia and replicable molecular features of the illness state.
Results
We performed deep poly(A) + RNA-sequencing of 495 individuals, ranging in age from the second trimester of fetal life to 85 years old ( Supplementary Table 1 ), including 175 patients with schizophrenia (see Supplementary Fig. 1 ). We quantified expression across multiple transcript features, including annotated (i) genes and (ii) exons and (iii) annotation-guided transcripts 6 , as well as alignment-based (iv) exon-exon splice junctions 7 and (v) expressed regions 8 . These last two expression features were selected to reduce reliance on the potentially incomplete annotation of the brain transcriptome 9 (Supplementary Note 1). We found a large number of moderately expressed and previously unannotated splice junctions that tag potential transcripts with alternative exonic boundaries or exon skipping ( Supplementary Fig. 2 ), 95% of which are also found in other large RNA sequencing (RNA-seq) datasets, including a subset that were brain-specific (Supplementary Table 2 ). Similarly, we found that only 56.1% of expressed regions were annotated to strictly exonic sequence-many expressed regions were annotated to strictly intronic (22.3%) or intergenic (8.5%) sequence, or were transcribed beyond existing annotation (for example, extended untranslated regions (UTRs), extended exonic sequence).
Developmental regulation of expression and shifting isoform usage. Characterizing expression changes in unaffected individuals, particularly across brain development beginning with prenatal life, has previously offered disease-relevant insights into particular genomic loci [10] [11] [12] [13] [14] . Specifically, we and others 9, 15, 16 have shown that genomic risk loci associated with neurodevelopmental disorders, The y axis is z-scaled expression (to standard normal); dark lines represent median expression levels, and confidence bands represent 25th-75th percentiles of expression level for each class of features. c, KEGG pathways enriched for genes with isoform shifts, stratified by which feature type identified the gene as having a switch. Color scale represents -log 10 (FDR) for gene set enrichment. Analogous data for gene ontology gene sets (biological processes and molecular function) are available in Supplementary Table 6 . DER, differentially expressed region; GnRH, gonadotropin-releasing hormone.
including schizophrenia, are enriched for transcript features showing differential expression between fetal and postnatal brains. Here too, among the 320 control samples, the strongest component of expression change corresponded to large cellular changes between prenatal and early postnatal life. RNA-based cellular deconvolution confirmed the decrease in the proportion of prenatal cell types, in line with previous data related to the loss of neural precursor cells at the transition of pre-and postnatal life 9 ( Fig. 1a and Supplementary Figs. 3 and 4). We further defined a developmental regulation statistic for each expressed feature using a generalized additive model for age (see Methods) and found widespread developmental regulation of these expressed features ( Supplementary Fig. 5 , Supplementary  Table 3 and Supplementary Note 2), including previously unannotated sequence ( Supplementary Table 4 ) that likely relates to the shifting cellular composition of the maturing brain 17 . We further demonstrated that these age-related changes in expression strongly related to cell-type-specific changes ( Supplementary Fig. 6 ). These developmental statistics and visualized expression trajectories from all features are available at http://eqtl.brainseq.org/phase1/devel. We then formally identified the subset of genes showing alternative isoform expression patterns across fetal and postnatal life using those exons, junctions, transcripts and expressed regions that met the statistical criteria for developmental regulation (i.e., those genes with at least one developmentally changing feature; see Methods). Supplementary Fig. 4 highlights CRTC2, a transcription coactivator, as representative of a gene with isoform shifts. There were 6,672 Ensembl genes (23.7% of the set of developmentally regulated genes) with both positive and negative expression features having genome-wide significant correlations with age (each with Bonferroni-corrected P < 0.05; Fig. 1b , Supplementary Fig. 5 and Supplementary Table 5 ), representing different transcript isoforms of the same gene that show opposite patterns of expression across the prenatal-postnatal transition. In principle, such a pattern could obscure developmental expression variation if measured only at the gene level and might better reflect how different cells in the human frontal cortex use the same gene differently across development.
We next performed gene set analyses of genes with shifting isoform usage, compared to the larger set of genes with developmentally regulated features but without shifting isoform usage, to identify more specific biological functions of this specific form of developmental regulation (Supplementary Table 6 ). The former set was enriched for localization; catalytic activity; signaling-related processes, including synaptic transmission and cell communication; and neuronal development. Notably, genes with shifting isoforms across development identified exclusively on the basis of junction counts were enriched for both dopaminergic (FDR = 1.67 × 10 −4 ) and glutamatergic (FDR = 2.04 × 10 −4 ) synapse KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways ( Fig. 1c ), the two major neurotransmitter systems most prominently implicated in schizophrenia pathogenesis and treatment.
Schizophrenia risk is associated with shifting isoform usage across brain development. Genes with developmental isoform shifts identified by exon, junction and expressed region counts were respectively 75% (P = 9.51 × 10 −6 ), 84% (P = 1.63 × 10 −7 ) and 71% (P = 2.0 × 10 −4 ) more likely to lie within the 108 schizophrenia GWAS risk regions or loci 2 (with permutation-based P = 0.02, P = 0.01 and P = 0.03 respectively; see Methods) than developmentally regulated genes without isoforms shifts (Supplementary Table 7 ). These enrichments were robust when controlling for both coding length and number of exons and were specific to schizophrenia, as we found no association for type 2 diabetes 18 , Parkinson's disease 19 or Alzheimer's disease 20 GWAS regions (all P > 0.05; see Methods). These results further underscore the role of changes in the regulation of transcription and splicing in the early brain developmental components in genomic regions implicated in schizophrenia risk.
Large-scale genetic regulation of transcript-specific and previously unannotated sequences. While the association of genomic loci with schizophrenia risk highlights potential enrichment of the genes within those loci, we sought to more directly assess the specific role of individual risk variants on nearby expression. We therefore first performed a genome-wide cis (within 500 kb) expression quantitative trait loci (eQTL) analysis within the 412 postadolescent subjects (see Methods) across the five convergent transcript features (Table 1 and Supplementary Note 3). Exon-level analysis showed widespread transcript specificity of eQTL associations: almost all exons with eQTL signal mapped to genes with more than one annotated transcript (N = 45,239, 94.2%), and the majority of these showed eQTL associations to exons belonging to a single transcript isoform (N = 30,283, 66.9%). This transcript specificity was also evident in the eQTL effect sizes, as the median additive effect size was approximately twice as high for exon-than gene-level analysis (15.6% versus 7.0% expression change per allele copy). Analyses focusing on annotation-agnostic expression levels further revealed extensive genetic regulation of previously unannotated transcript sequences, including newly identified exon-skipping, shifted exonic boundary splice junctions, as well as entirely intronic and intergenic sequence ( Table 1 and Supplementary Note 3). These results demonstrate extensive transcript specificity of many eQTL signals that are missed by traditional annotation-dependent analyses. Given the large degree of genetic regulation of transcript specificity and unannotated sequences, we sought to confirm the identified eQTLs in our dataset (hereafter, "LIBD") in independent human brain RNA-seq data from the CommonMind Consortium ("CMC") dorsolateral prefrontal cortex project 4 (using ribosomal depletion; see Methods). Among those significant eQTL SNP-feature pairs that were well imputed, polymorphic and expressed in the replication dataset (~84% of pairs, ~95% of expressed features with eQTLs; see Methods and Supplementary Fig. 6 ), > 94% had consistent directionality in the two datasets: between 75.7% (transcripts) and 81.5% (junctions) were directionally consistent and marginally significant (at P < 0.01), and just over half (52.1-57.0%) were directionally consistent and FDR-corrected significant (published set, P < 10 −5 ). Meta-analysis between datasets demonstrated extensive significance and replication of the 9.3 million SNP-feature Bonferroni-significant eQTL pairs, including 97.6% at P < 10 −5 and 82.0% at P < 10 −9 . We further reprocessed and quantified Genotype-Tissue Expression Consortium v6 RNA-seq brain data ("GTEx") from raw reads using the same LIBD pipeline and assessed replication and regional specificity in these data using meta-analysis across 13 brains regions compared to frontal cortex alone. Here we found that almost all of the eQTLs identified in dorsolateral prefrontal cortex showed strong concordant signal across all brain regions, suggesting an overall lack of regional specificity for the majority of our identified eQTLs ( Supplementary Fig. 7 ). All significant eQTLs are searchable on our publicly available database, http://eqtl.brainseq.org/phase1/eqtl/, which provides visualizations and eQTL statistics across the three independent datasets. eQTL associations to schizophrenia and other traits. We interrogated the potential clinical relevance of our full catalog of significant eQTLs particularly in the context of transcript feature-level and previously unannotated sequence associations using published GWAS risk variants. We first considered the common (minor allele frequency > 5%) and well-measured risk variants from the 128 index variants (N = 106; see Methods) in the latest GWAS for schizophrenia 2 and their highly correlated proxies (see Methods). We identified FDRsignificant eQTL associations to 51 risk SNP signals (of 106 tested, 48.1%; Supplementary Table 8 ), a substantially higher proportion of risk variants classified as brain eQTLs than previously reported 4 ( Table 2 ). In total, there were 1,244 unique SNP-feature pairs that were genome-wide FDR-significant eQTLs (at FDR < 1%; 83 genes, 553 exons, 49 transcripts, 192 junctions and 367 expressed regions) mapping to 194 unique Ensembl gene identifiers (of which 162 have Human Genome Organisation gene symbols). Among these 51 risk SNPs, 17 were eQTLs to only exons, junctions or expressed regions, and 7 were eQTLs to only unannotated transcribed sequence. These unannotated sequences were enriched for transcriptional chromatin states in brain and other tissues in the Epigenome Roadmap compared to the rest of the genome ( Supplementary Fig. 8a ). There were only 17 loci with annotated eQTLs to only a single gene and another 10 loci with eQTLs to two genes.
We also assessed enrichment of 23,704 GWAS risk SNPs from the National Human Genome Research Institute (NHGRI) GWAS catalog present and common in our genetic data (of 44,738 available) and found eQTL evidence for 8,988 variants (37.9%) at FDR < 0.01. These GWAS variants that were identified as eQTLs were from GWAS for the majority of all tested traits in the literature (68.1%, 1,415 of 2,078 present) across all sites in the body, suggesting that many of the identified eQTLs in brain are likely shared with other tissue sites, as previously described 21 . Of the 8,988 GWAS eQTL variants, 2,982 were eQTLs only to exons, junctions or expressed regions, of which 995 were only to unannotated sequence ( Table 2) , which were also enriched for transcriptional chromatin states in human cell types and tissues ( Supplementary Fig. 8b ). These results emphasize the important of identifying eQTL signals for clinical risk variants by casting a wider net of RNA-seq feature summarization, including previously unannotated transcribed sequences.
Refining eQTL associations through conditional analyses. We used conditional analyses to partition the GWAS-associated eQTLs to better identify the downstream molecular features of genetic risk. For each of the 51 GWAS variants with eQTLs, we iteratively conditioned on the most significant eQTL feature for each variant and then performed eQTL reanalysis of all other features. These analyses resulted in 238 conditionally independent SNP-feature eQTLs (35 genes, 73 exons, 9 transcripts, 55 junctions and 66 expressed regions) to the 51 schizophrenia GWAS variants (Supplementary Table 8 ) that mapped to 130 unique Ensembl gene identifiers. Conditional analysis resulted in an additional locus with eQTLs to a single gene (totaling 18 loci) and an additional 5 loci with eQTLs to features in two genes (totaling 15 loci; Table 3 ). Notably, these conditional analyses further highlighted the potential importance of transcript-specific and previously unannotated eQTLs, as more loci were associated only with exons, junctions and expressed regions (27 versus 17), more were strictly unannotated (11 versus 7), and more showed eQTL associations to a single annotated transcript isoform (18 versus 11).
In Fig. 2 , we highlight select eQTLs for different classes of associations. The top GWAS risk variant rs1233578 associated with strictly intergenic sequence downstream of ZSCAN23 ( Fig. 2a ,b, P = 2.7 × 10 −8 ), as confirmed in both CMC (P = 0.01) and GTEx (t = 3.1), suggesting potential novel transcribed sequence linked to schizophrenia risk. We also found significant eQTL signal to specific 5′ junction and exon sequences of CTNNA1 to rs3849046 ( Fig. 2c ,d; discovery P = 6.2 × 10 −8 , CMC replication P = 1.4 × 10 −8 ). Another example of eQTL associations of partially annotated sequence was rs9841616 exclusively associating with the 3′ sequence of the most proximal short transcript isoform of SOX2-OT ( Fig. 2e ,f; discovery P = 8.2 × 10 −12 , CMC P = 2.9 × 10 −8 ). We also found novel eQTL associations to annotated exons in CD46 ( Fig. 2g , P = 9.2 × 10 −38 , CMC P = 2.9 × 10 −14 ), SRR ( Fig. 2h , P = 2.0 × 10 −12 , CMC P = 4.7 × 10 −6 ) and GPM6A ( Fig. 2i , P = 2.8 × 10 −6 , CMC P = 0.02). We did find significant enrichment of these conditionally independent schizophrenia risk-associated eQTLs among genes with developmental isoform shifts identified above-44.0% of genes with eQTLs compared to 23.6% without eQTLs (OR = 2.54, P = 5.38 × 10 −8 ). These conditional analyses suggest potential regulatory roles of these unannotated transcribed sequences on annotated transcripts that play a putative role in the manifestation of schizophrenia risk in brain. More generally, these eQTL results demonstrate significant and independently replicated risk-associated schizophrenia candidate genes and their specific transcripts that comprise links in the causative chain of schizophrenia in the human brain.
Expressed features associated with chronic schizophrenia illness state. Genetic association with gene expression is an approach to understanding the molecular mechanisms of risk, but it does not directly address the molecular landscape of the illness state. We therefore explored schizophrenia illness state-associated expression dif-ferences and their potential link with developmental regulation and genetic risk. We performed differential expression modeling using 351 high-quality adult samples (age > 16, 196 controls, 155 cases) and found extensive bias by RNA degradation within both univariate analysis (where 12,686 genes were differentially expressed at FDR < 5%), even after adjusting for standard measured levels of RNA quality typical of all prior studies. We therefore implemented a recently described statistical framework based on an independent molecular degradation experiment (see Methods and Supplementary Note 4), called quality surrogate variable analysis (qSVA; see Methods) 5 . We evaluated potential replication RNA-seq data from the CMC dataset, using a subset of age-range-matched 159 schizophrenia patients and 172 controls. Notably, adjusting for observed factors related to RNA quality that were used by all earlier studies of gene expression in schizophrenia-affected brain, including an earlier report using CMC data 4 , the proportion of genes with differentially expressed features at genome-wide significant FDR < 5% that replicated (with directionality and marginal significance at P < 0.05) in the CMC dataset was very small (11.0%). In contrast, using qSVA, 40.1% of differentially expressed genes at FDR < 5% (N = 75/183) replicated in CMC data. At FDR < 10% (see Methods), we identified 237 genes with 556 differentially expressed features that replicated in the CMC dataset (33.6% gene-level replication rate; Supplementary Tables 9 and 10 ). Case-control statistics from both discovery and replication datasets, as well as box plots from all expressed features, are available at http://eqtl.brainseq.org/phase1/sz. The differences in expression levels between cases and controls of these differentially expressed features were generally small in both discovery and replication data ( Fig. 3a and Supplementary Fig.  12 ), in line with the clinical and molecular heterogeneity of this disorder 15, 22 . Gene ontology analysis implicated transporter-and channel-related signaling as significantly consistently downregulated in patients compared to controls across genes annotated in all three expression summarizations ( Fig. 3b and Supplementary Table 11 ).
These results might suggest decreased signaling in patients with schizophrenia, but also raise the possibility that these replicated expression differences between patients and controls relate to epiphenomena of illness, such as drug treatment, which is known to affect signaling in the brain 16 , as the majority of patients were on antipsychotics at the time of death (64%; Supplementary Table 1 ). While only two genes located in the 108 schizophrenia GWAS loci 2 were significantly differentially expressed (KLC1 and PPP2R3A), we found significant associations comparing the genome-wide differential expression statistics within versus outside of the GWAS significant loci, although the absolute biological effects were small ( Supplementary Fig. 13 , Supplementary Table 12 and Supplementary Note 5). We also investigated the relationships between expression and genomic risk for schizophrenia using genome wide polygene risk scores (PRS) from each subject calculated as previously described 2 (see Methods) and found no association between PRS and expression of individual expression features, no enrichment of PRS on expression comparing the differentially expressed and replicated case-control features, and no directional consistency between PRS-and diagnosis-associated statistics among expressed features ( Supplementary Table 13 ). These results indicate that the significant case-control expression differences show little overlap with genetic risk for the disorder.
In an earlier study of the epigenetic landscape of frontal cortex of patients with schizophrenia, we showed that DNA methylation levels in patients were closer to fetal methylation levels than to those of adult control samples 17 . Here we tested for analogous effects in the RNA-seq data related to the illness state. Every significant gene with differentially expressed features in the adult case-control analysis and replicated in the independent dataset showed evidence for developmental regulation across at least two expression feature types. We further found that expression features more highly expressed in postnatal life tended to be more weakly expressed in patients compared to controls (maximum: P = 3.24 × 10 −11 , minimum: P = 1.05 × 10 −70 ; Fig. 3c ) and features more highly expressed in fetal life tended to be more highly expressed in patients with schizophrenia compared to controls (maximum: P = 6.86 × 10 −33 , minimum: P < 10 −100 ; Fig. 3d ). Analogous tests of developmental regulation of schizophrenia-associated features without adjusting for the RNA quality surrogate variables were significant in the opposite directions-namely, schizophreniaassociated changes were further from, rather than closer to, fetal expression levels, as might be predicted as a confounding artifact of residual RNA quality differences ( Supplementary Table 1 ).These results further converge on a role for gene expression changing during brain development and maturation in the pathogenesis of schizophrenia, specifically that both DNA methylation and expression levels in adult patients appear to reflect levels in the developing brain more strongly than do those of unaffected individuals.
Discussion
We have explored the diverse landscape of expression correlates of schizophrenia risk and illness state in the postmortem human frontal cortex across the lifespan. Using deep RNA sequencing to define convergent measures of gene expression and early brain development, we identified widespread developmental regulation of expression, including discoveries related to preferential isoform usage across brain development. These unexpected isoform shifts were associated with genetic risk for schizophrenia, and the directionality of dysregulation of developmentally regulated features suggest a more fetal-like expression profile in patients with schizophrenia compared with controls. Our approach to transcript characterization, which included extensive characterization of unannotated sequence, revealed that many more top independent schizophrenia risk associated SNPs are brain eQTLs than previously reported: many risk SNPs only associate with a single gene, or even a single transcript, and many of these adult-identified eQTLs show overlap with genes with dynamic isoform regulation across human brain development. Lastly, we identified significant and replicated genes differentially expressed in patients with schizophrenia compared to unaffected controls using an experiment-based framework to better model RNA quality. It is important to note that while much of the signal relating to developmental regulation likely relates to changing cellular composition across brain development, the use of latent variable adjustment in the diagnosis and eQTL modeling likely controls for these effects 23 . These data, therefore, could suggest a convergence of developmental regulation and genetic risk for schizophrenia that appears relatively stable in patients ascertained at death, following decades of illness after diagnosis. We previously observed analogous stability of epigenetic marks highlighting prenatal life in adult patients with schizophrenia 17 , suggesting that both genetic and environmental risk factors implicated in schizophrenia illness involve early developmental events that are still observable in the brain tissue of adult individuals despite many years of illness. While our approach using convergent expression featuresgenes, exons, transcripts, junctions and expressed regionsinvolves more complicated data processing and analysis, it casts a wider net in the search for signals in RNA-seq data. Using all convergent features overcomes the limitations related to any given feature summarization, including the inability to measure and interrogate unannotated or novel transcribed sequences using gene and exon counts and the difficulties in full transcript assembly from short sequencing reads 24 . We note that both quantifying and analyzing splice junctions and transcripts rely on junction-spanning reads for statistical power, which are approximately threefold depleted compared to those assigned to exons, likely explaining why gene counts discovered more differentially expressed genes in the schizophrenia diagnosis analyses. Two relatively new approaches used here, direct quantification and statistical analyses of splice junction counts and expressed regions, can identify differential expression signal when it is outside the annotated transcriptome. The junction-level approach can also identify previously uncharacterized transcribed sequences, which we replicated in other large, publicly available datasets, as well as delineate individual transcripts or classes of transcripts that share a particular splice junction. As read lengths increase, the proportion of reads containing splice junctions will increase, making junction-and transcript-based approaches even more powerful, including those recently developed to identify splicing QTLs 25 .
Our analysis of RNA-seq data identified widespread shifts in preferential isoform use across brain development and its changing cellular landscape, which would have been impossible to identify using only gene-level data and incomplete with only exon-level data (Fig. 2) . The genes with these isoform shifts were significantly enriched for neurodevelopmental and cellular signaling processes, as well as for genes in regions of genetic risk for schizophrenia. A prevalent hypothesis suggests that schizophrenia is a neurodevelopmental disorder that arises because of altered connectivity and plasticity in the early assembly of relevant neural circuits 26 . Thus, the potential convergence of genetic risk with developing signaling processes across human brain development should point to specific candidate molecular disruptions occurring during the wiring of the fetal brain. Indeed, inefficient or disrupted signaling and tuning is thought to underlie the expression of illness in the adult brain 26 , and the most successful therapeutics work through improving these processes 16 . Consistent with this hypothesis, we find evidence for differences in the expression of genes encoding subunits of ion channels in the cortices of patients with schizophrenia compared to controls. We observed significant differential expression of both voltage-gated (KCNA1, KCNC3, KCNK1, KCNN1, SCN9A) and ligand-gated ion channels (GRIN3A, GABRA5, GABRB3), transporters (SLC16A2, SLC25A33, SLC26A11, SLC35F2, SLC7A3) and ion channel auxiliary subunits (KCNIP3, SCN1B), supporting other evidence that the clinical phenomenology of schizophrenia is associated with altered neuronal excitability 27 . While these findings implicating basic mechanisms of cortical circuit dynamics may underlie fundamental aspects of the clinical disorder, the possibility that at least some are driven by the effects of pharmacological treatment and are thus state-dependent epiphenomena cannot be excluded. Indeed, our failure to find association of genomic risk scores and differential gene expression in the illness state adds some weight to the latter interpretation.
Our data also suggest more widespread regulation of specific transcript isoforms than previously reported, which we were able to identify using exon-and junction-level analyses. This transcriptspecific genetic regulation was particularly prevalent among schizophrenia risk variants, where 66.9% of loci containing multiple transcripts showed clinically and molecularly consistent eQTL signal to a single Ensembl transcript isoform. Overall, we have identified many more eQTLs to genome-wide significant schizophrenia risk variants-48.1%-than had been previously reported, implicating far more potential risk genes within these loci than previously characterized. Our publicly available database of eQTLs is searchable for candidate genes or SNPs and provides publication-ready visualizations (for example, the box plots in Fig. 2 ). It is a 'one-stop shop' for eQTL statistics across three independent studies (LIBD, CMC and GTEx) for both annotated and unannotated transcribed sequence in the human cortex, and it can export results to the UCSC Genome Browser 28 for additional interrogation.
We have highlighted GWAS loci that contain significant and statistically independent eQTLs, as they often point to individual risk genes or even more specific risk transcripts. These risk genes and transcripts are targetable entry points for more focused cellular assays and model organism work to better characterize schizophrenia risk mechanisms. Moreover, these eQTLs of specific transcript features identify a compelling strategy: to increase or decrease the function of the protein produced by the putative risk transcript(s) and downstream effectors. Focusing solely on increased or decreased expression in brains of patients compared to controls, without considering genetic risk variants and their regulation of local gene expression, will likely predominantly focus on molecular changes resulting from the schizophrenia illness state, as we suggest with consistent downregulation of ion channels. We stress the priority of identifying the most relevant cellular consequences of genetic risk, which we view as production of particular isoforms with predicted directionality, rather than trying to identify supposedly 'causal' mutations tagged by 'marker' risk SNPs from the GWAS. We suggest that utilizing the convergence between genetic risk and specific potential molecular consequences in the disorder is likely to result in better-or at least more consistent support fortargets for drug discovery efforts.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0197-y.
Postmortem brain samples. Postmortem human brain tissue was obtained by autopsy primarily from the Offices of the Chief Medical Examiner of the District of Columbia and of the Commonwealth of Virginia, Northern District, all with informed consent from the legal next of kin (protocol 90-M-0142 approved by the NIMH/NIH Institutional Review Board). Additional postmortem fetal, infant, child and adolescent brain tissue samples were provided by the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders (http://www.BTBank.org) under contracts NO1-HD-4-3368 and NO1-HD-4-3383. The Institutional Review Board of the University of Maryland at Baltimore and the State of Maryland approved the protocol, and the tissue was donated to the Lieber Institute for Brain Development under the terms of a Material Transfer Agreement. Clinical characterization, diagnoses, and macro-and microscopic neuropathological examinations were performed on all samples using a standardized protocol, and subjects with evidence of macro-or microscopic neuropathology were excluded. Details of tissue acquisition, handling, processing, dissection, clinical characterization, diagnoses, neuropathological examinations, RNA extraction and quality control measures were described previously by Lipska et al. 29 . The Brain and Tissue Bank cases were handled in a similar fashion (http://www.medschool.umaryland.edu/ btbank/Medical-Examiners-and-Pathologists/Minimum-Protocol/). Antipsychotic use was measured using toxicology at time of death. Given the retrospective nature of this project, data collection and analysis were not performed blind to the conditions of the experiments.
RNA extraction and sequencing. Postmortem tissue homogenates of dorsolateral prefrontal cortex gray matter (DLPFC) approximating Brodmann area 46/9 in postnatal samples and the corresponding region of PFC in fetal samples were obtained from all subjects. Total RNA was extracted from ~100 mg of tissue using the RNeasy kit (Qiagen) according to the manufacturer's protocol. The poly(A)-containing RNA molecules were purified from 1 µ g DNase-treated total RNA, and sequencing libraries were constructed using the Illumina TruSeq RNA Sample Preparation v2 kit. Sequencing index barcodes were inserted into Illumina adapters allowing samples to be multiplexed across lanes in each flow cell. These products were then purified and enriched with PCR to create the final cDNA library for high-throughput sequencing using an Illumina HiSeq 2000 with paired-end 2 × 100 bp reads. While poly(A) + libraries tend to be biased toward the 3′ end of transcripts (a bias that increases as RNA quality decreases), our higher starting RNA quality (for postmortem studies) allowed us to generate high-quality sequencing data ( Supplementary Table 1 ). No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 4 . We attempted to balance samples by diagnosis and age across sequencing batches to reduce technical biases.
RNA sequencing data processing. The Illumina Real Time Analysis (RTA) module performed image analysis, base calling and the BCL Converter (CASAVA v1.8.2), generating FASTQ files containing the sequencing reads. These reads were aligned to the human genome (UCSC hg19 build) using the spliced-read mapper TopHat (v2.0.4) using the reference transcriptome to initially guide alignment, based on known transcripts of the previous Ensembl build GRCh37.67 (the -G argument in the software) 30 . We achieved a median of 85.3 million (IQR: 71.7 million-111.2 million) aligned reads per sample (see Supplementary Table 1 ).
We characterized the transcriptomes of these 495 samples using five convergent measurements of expression ('feature summarizations'): (i) gene and (ii) exon counts and (iii) transcript-level quantifications that rely on existing gene annotation, and two annotation-agnostic approaches we have developed that are determined solely from the read alignments, (iv) read coverage supporting exonexon splice junctions (for example, coordinates of potentially intronic sequence that are spliced out of mature transcripts captured by a single read) and (v) read coverage overlapping each base in each sample, which we have summarized into contiguous 'expressed regions' (ERs; Supplementary Fig. 1 ). These last three measurements generate expression for features of interest that can 'tag' elements of transcripts in the data that are not constrained by limitations or incompleteness of existing annotation, and the counts for these features can then be directly used for differential expression analysis.
1. Gene counts were generated using the featureCounts tool 31 (v1.4.3-p1) based on the more recent Ensembl v75, which was the last stable release for the hg19 genome build, using single-end read counting (featureCounts -a $GTF -o $OUT $BAM). We converted counts to RPKM values using the total number of aligned reads across the autosomal and sex chromosomes (dropping reads mapping to the mitochondrial chromosome). As our libraries were unstranded, reads that mapped to exons belonging to genes on different strands were excluded from counting (which is the default behavior of the tool).
2. Exon counts were also generated using the featureCounts tool 31 (v1.4.3-p1) based on the more recent Ensembl v75, using single-end read counting and allowing reads to be assigned to multiple exons (for example, those with splice junctions) (featureCounts -O -f -a $GTF -o $OUT $BAM). We converted counts to RPKM values using the total number of aligned reads across the autosomal and sex chromosomes (dropping reads mapping to the mitochondrial chromosome).
3. Junction counts were generated by first filtering the TopHat BAM file to primary alignments only (samtools view -bh -F 0 × 100 $BAM > $NEWBAM), and regtools 32 (v 0.1.0) was used to extract analogous junction information (coordinates and number of reads supporting) as the TopHat output. We found that native TopHat output (junctions.bed) was based on both primary and secondary alignments, which could influence the degree of potentially novel splice junctions. We used a modified version of TopHat's bed_to_juncs program to retain the number of supporting reads (in addition to returning the coordinates of the spliced sequence, rather than the maximum fragment range) and used R code (see https://github.com/LieberInstitute/BrainSeq_Phase1/) to combine and annotate these junctions across all samples. We identified splice junctions using Ensembl v75; while the initial alignment was guided by Ensembl v67, novel junctions, by definition, are identified in the second genome alignment, rather than the initial guided transcriptome alignment step. We converted counts to RP80M values (reads per 80 million mapped) using the total number of aligned reads across the autosomal and sex chromosomes (dropping reads mapping to the mitochondrial chromosome), which can be interpreted as the number of reads supporting the junction in an average library size (we were targeting 80 million reads in the sequencing). Most junctions were expressed at low levels in our homogenate tissue, with fewer than 1 average normalized supporting read (N = 3,330,642; 92.98%), including approximately half unique to a single individual (N = 1,779,241, 49.67%).
4. Transcripts were assembled using StringTie 6 (version 1.1.2) guided by Ensembl v75 annotation within each sample (stringtie $BAM -o $OUT -G $GTF). We then used CuffMerge 33 (version 2.2.1) to merge all assembled transcriptomes across all samples and then requantified the expression of each transcript isoform in each sample again using StringTie to this global set of transcripts (stringtie $BAM -B -e -o $OUT -G $GTF_ALL) to have expression measurements on the same transcripts across all samples. We then used the ballgown tool 34 to merge all assembled and quantified transcripts across all samples (N = 733,339) and used liberal filtering to remove weakly or uniquely expressed transcripts (mean FPKM > 0.025), resulting in 188,578 transcripts across the 495 samples.
5. ERs were calculated using the derfinder R Bioconductor package 8 using a cutoff of 5 normalized (to 80 million reads) read coverage, which identified 389,797 ERs. We retained the 275,885 ERs that were at least 12 bp and annotated the ERs to Ensembl v75.
Genotype data processing. SNP genotyping with HumanHap650Y_V3 (N = 135), Human 1M-Duo_V3 (N = 357) and Omni5 (N = 3) BeadChips (Illumina, San Diego, CA) was carried out according to the manufacturer's instructions with DNA extracted from cerebellar tissue. Genotype data were processed and normalized with the crlmm R/Bioconductor package 35 separately by platform. Genotype imputation was performed on high-quality observed genotypes (removing lowquality and rare variants) using the prephasing/imputation stepwise approach implemented in IMPUTE2 36 and Shape-IT 37 , with the imputation reference set from the full 1000 Human Genomes Project Phase 3 dataset, separately by platform. We retained common SNPs (MAF > 5%) that were present in the majority of samples (missingness < 10%) that were in Hardy-Weinberg equilibrium (at P > 1 × 10 −6 ) using the Plink 38 version 1.9 tool kit (plink --bfile $BFILE --geno 0.1 --maf 0.05 --hwe 0.000001). We then identified linkage disequilibrium (LD)-independent SNPs to use in genome-wide clustering of samples and in the number of independent eQTL tests performed (plink --bfile $BFILE --indep 100 10 1.25). Multidimensional scaling (MDS) was performed on the autosomal LDindependent construct genomic ancestry components on each sample, which can be interpreted as quantitative levels of ethnicity-the first component separated the Caucasian and African American (as reported by the Medical Examiner's office) samples. This processing and quality control steps resulted in 7,421,423 common variants in this dataset of 495 subjects.
Public data processing. GTEx. Raw RNA-seq reads from all brain samples with corresponding genotype data were downloaded from SRA and aligned to the genome using TopHat2 30 (version 2.0.14) using the iGenomes transcriptome and genome annotations based on hg19. As above, featureCounts 31 was used to quantify expression of genes and exons relative to Ensembl v75, and junctions were quantified with regtools 32 as above. We used StringTie with the assembled merged GTF from the LIBD DLPFC samples on the GTEx BAM files to quantify the same transcripts and used bwtool 39 to quantify the coverage of the same expressed regions from the GTEx brain samples. Genotype data from the two platforms (Illumina Omni 5 M and 2.5 M) were imputed separately as described above and merged into a single plink 38 set.
GEUVADIS. Raw RNA-seq reads from all LCL samples were downloaded from SRA and aligned to the genome using TopHat2 30 (version 2.0.9) using the iGenomes transcriptome and genome annotations based on hg19. As above, featureCounts 31 was used to quantify expression of genes and exons relative to Ensembl v75, and junctions were quantified with regtools 32 as above. We used StringTie with the assembled merged GTF from the LIBD DLPFC samples on the GEUVADIS BAM files to quantify the same transcripts and used bwtool to quantify the coverage of the same expressed regions from the GEUVADIS LCL samples.
CommonMind Consortium (CMC) . 547 BAM files were downloaded from Synapse, which were aligned with TopHat2 (version 2.0.9) using Ensembl v70 transcriptome annotation and the hg19 genome. As above, featureCounts 31 was used to quantify expression of genes and exons relative to Ensembl v75, and junctions were quantified with regtools 32 as above. We used StringTie with the assembled merged GTF from the LIBD DLPFC samples on the CMC BAM files to quantify the same transcripts and used bwtool to quantify the coverage of the same expressed regions from the CMC brain samples. Genotypes were converted to plink file sets from GEN files obtained from Synapse using posterior probabilities > 90%, resulting in genotype data across 9,506,038 SNPs and 547 samples.
Differential expression across brain development. We modeled differential expression across age at each of the five feature summarizations (gene, exon, junction, transcript and ER) in the 320 control subjects across the lifespan. We modeled expression, after transforming log 2 with an offset of 1 (to better fulfill the assumptions of linear regression), as a function of age after creating using linear splines with breakpoints at ages birth (0), 1, 10, 20 and 50, further adjusting for sex and ancestry/ethnicity (first three MDS components). F-statistics were computed comparing the model containing age (including the linear splines), sex and ethnicity to a statistical model with just sex and ethnicity, with corresponding P-values calculated based on an F-distribution with 7 and 308 degrees of freedom, and Bonferroni adjustment within each feature type was performed using the number of features with nonzero expression (gene RPKM > 0.01, exon RPKM > 0.1, and junction RP80M > 0.2 with non-novel annotation) across all samples as the number of tests (which varied by feature type). We also computed post hoc statistics on the data, including the Pearson correlation between 'cleaned' expression (after regressing out the effects of sex and ethnicity, holding the age effects constant) and age, to determine whether the fetal expression rose or fell across the lifespan, and also measured the fetal versus postnatal log 2 fold changes.
Preferential isoform usage across aging was determined by identifying the subset of genes (by Ensembl ID) that contained at least one Bonferroni-significant feature that had positive correlation with age and another Bonferroni-significant feature that had negative correlation with age. Specifically, we performed the following:
1. Fitting a (linear) spline model using all samples (N = 320) with break points at birth (0), 1, 10, 20 and 50 years of age at all expressed features, further allowing an offset at birth (i.e., the slope in prenatal life does not connect to the slope between birth (age 0) and age 1 (since we did not have third-trimester prenatal samples), further adjusting for sex and ethnicity. Examples of the spline fit are shown in Supplementary Fig. 4b-h. 2. Calculating an F-statistic comparing this full model (age spline, sex, ethnicity) to a null model containing just sex and ethnicity) and Bonferroniadjusting the resulting P-values for this F-statistic within each feature summarization type (gene, exon, junction, transcript and ER).
3. Calculating post hoc Pearson correlation coefficients comparing age and log 2 fold changes comparing pre-and postnatal samples for all features; note there are no P-values retained from nor statistical inference performed from these correlations.
4. Then, for a given gene and feature summarization type (exon, junction, transcript and ER), filtering to only Bonferroni-significant features and checking whether there is at least one feature with positive age correlation and another feature with negative age correlation.
We also computed the difference in positive and negative correlations as a measure of the magnitude of the preferential isoform use, which showed linear replication with the BrainSpan 40 project (i.e., computing the same age correlations in identically processed and summarized data; Supplementary Fig. 14) . Gene set analyses using predefined gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) sets were performed using the clusterProfiler R/Bioconductor package 41 , here using the genes (mapping from Ensembl to Entrez ID) that had such preferential isoform use to those that were developmentally regulated (having at least one feature that was associate with age at Bonferroni significance). Enrichments with the 108 GWAS schizophrenia risk loci 2 -defined by the chr:start-end roughly corresponding to linkage disequilibrium blockswere performed both parametrically, by overlapping the genomic coordinates of the 108 risk regions with those genes that had preferential isoform usage, compared to a background of all genes with each set of expressed features, and by permuting the locations of the 108 regions across the genome 10,000 times and each time, recomputing the overlap within these null regions. See details in Jaffe et al. 2015 9 . Empirical P-values were calculated by counting the number of the odds ratios across the 10,000 null permutations to each observed odds ratio.
We performed sensitivity analyses to assess the role of gene length on these GWAS enrichments of isoform switch genes, using either the coding length (log 2transformed) or the number of exons (log 2 -transformed). We assessed confounding factors using logistic regression analysis among all expressed genes, computing the odds of genes with isoform shifts being within the risk loci, within and without adjusting for these gene length variables. Schizophrenia GWAS enrichments at the exon and junction level remained significant and approximated the empirical P-values obtained from permutation (as the act of randomly permuting GWAS regions should have removed potential confounding factors). We performed analogous logistic regression analyses using GWAS LD regions from type 2 diabetes 18 , Parkinson's disease 19 and Alzheimer's disease 20 , adjusting for the log 2 coding length, and found no association to genes with isoform shifts in the developing cortex.
Reference-based cellular deconvolution. We analogously processed RNA-seq data from Darmanis et al. 42 consisting of 25 replicating and 110 quiescent fetal neurons, 18 oligodendrocyte progenitor cells (OPCs), 131 neurons, 62 astrocytes, 38 oligodendrocytes,16 microglia and 20 endothelial cells. We defined stagespecific genes using the same framework described by Jaffe and Irizarry 2014 23 , which involved creating a 'barcode' of 40 genes per cell type, such that 20 genes were more highly expressed and another 20 genes were more weakly expressed for one stage compared to all others (t-statistic P < 1 × 10 -8 ), and ranking subsequent significant genes by log 2 fold changes for selection. From our final set of 258 unique genes, we scaled each gene expression value to the standard normal distribution to improve comparability between single-cell and bulk RNA-seq data and created the regression calibration design matrix based on Houseman et al. 43 ( Supplementary Table 14 ). We then projected samples into the design matrix using the projectCellType() function in the minfi Bioconductor package 44 . eQTL discovery analyses. We performed eQTL analyses separately by feature type (gene, exon, junction, transcript and ER) allowing for a 500-kb window around each of the 7,421,423 common SNPs in the 412 age > 13 samples, adjusting for ancestry (first three MDS components from the genotype data), sex, diagnosis and the first K principal components (PCs) of the normalized expression features, where K was calculated separately by feature type using the Buja and Eyuboglu permutation-based algorithm 45 47 , which returned the log 2 fold change per allele copy and corresponding t-statistic, P-value and FDR for each SNP-feature pair. We further used the LD-independent SNPs to estimate the effective number of tests (by counting the number of features within a 500-kb window around each LD independent SNP) for a more conservative Bonferroni adjustment. For all five feature types, we retained all eQTLs with FDR < 1%. eQTL replication analyses. We sought to replicate all significant SNP-feature pairs for each eQTL in two independent datasets, CommonMind Consortium and the GTEx project, across all five feature summarizations. We used chromosome and position of variants to attempt to match across datasets-almost all SNPs in the discovery sample were present in each replication sample. Within each dataset, we tested all polymorphic SNPs (i.e., not monomorphic) and corresponding expressed features, adjusting for the first ten PCs of each feature summarization type and the first five MDS components of the corresponding common genotype data. Analyses within CMC were performed on the 285 controls and analyses in GTEx were performed within each brain region separately. After identifying and matching back on SNP-feature eQTL pairs, we checked whether the counted alleles were the same within the discovery and replication datasets and flipped the directionality of eQTL associations where the alleles were discordant. Note that in GTEx, some residual discordancy was still present across datasets (for example, off-diagonal points in Supplementary Figs. 6 and 7a,b) but not within a dataset ( Supplementary  Fig. 7c ). Meta-analysis between discovery (LIBD) and CMC was performed using Stouffer's methods 48 , by summing the t-statistics and dividing by the square root of the number of datasets (N = 2). Meta-analysis within GTEx brain regions was performed using the same approach, here dividing by the square root of number of datasets/brain regions (N = 13). When replication statistics were not present in replication datasets owing to no or low expression or to being monomorphic, the discovery eQTL was penalized by setting the replication statistic to 0 before meta-analysis. eQTL clinical enrichment analyses. We downloaded the 128 linkagedisequilibrium-independent variants that reached genome-wide significance in combined analysis from the published schizophrenia GWAS 2 and matched those variants to our data by chromosome and position relative to hg19. Of the 128 variants, only 106 were present in our final QCed and common (MAF > 5%) genotype data. Most were excluded owing to MAFs less than 5%, although several variants were dropped for other reasons (not present in 1000 Genomes, failed Hardy-Weinberg equilibrium, poorly imputed, etc.). We therefore interrogated only those 106 schizophrenia-associated variants among our eQTL associations. We used a similar strategy for the latest NHGRI GWAS catalog (downloaded 24 July 2017) with an additional step of lifting over our variants to hg38 and again matching by variant coordinates. Here, only approximately half of the variants were well measured in our samples ( Table 2 ). We used three significance levels to associate eQTLs with GWAS variants: (i) more liberal FDR-significant eQTLs in the discovery dataset, (ii) these FDR-significant eQTLs with additional replication data support (meta-analysis P-values with CMC < 10 −8 ), and (iii) Bonferronisignificant eQTLs in the discovery dataset; for example, Table 1 . We assessed the chromatin state enrichments of unannotated sequences associated with these risk variants using published data from the 15-state ChromHMM Epigenome Roadmap project 49 . We evaluated the set of ER eQTL features that were completely novel in 1 nature research | life sciences reporting summary 
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Experimental design 1. Sample size
Describe how sample size was determined. N=495 (Discovery) -This was established based on the brain tissue on hand and the money available for sequencing. However, we have previously shown that developmental changes in brain expression require much smaller sample sizes; previous eQTL analyses and power calculation by GTEx suggested that this sample size was well-powered for eQTLs; previous analyses and power calculations suggested this sample size was well-powered for casecontrol expression differences.
Data exclusions
Describe any data exclusions.
We only included samples from the two main ethnicities in our brain collection -Caucasian and African American.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
We have downloaded and uniformly processed and quantified data from the CommonMind Consortium and the GTEx project. We also report replication p-values and statistics for expression features differentially expressed in schizophrenia and also for eQTLs identified in the DLPFC
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
This was an observational study from postmortem human brain tissue and thus subjects were not randomized into outcome groups. Subjects were diagnosed using medical records and next-of-kin interviews as described in the paper.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded to group allocation since the study was observational Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
nature research | life sciences reporting summary
November 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
TopHat2 (v2.0.4 and v2.0.9), R/Bioconductor (limma, GenomicRanges, MatrixEQTL, sva, clusterProfiler, derfinder, derfinderPlot, minfi, crlmm), featureCounts (v1.4.3-p1) , StringTie (v 1.1.2), regtools (v0.1.0), CuffMerge (v 2.2.1), plink (v1.9), bwtool. More information is availabe at our GitHub repository: https://github.com/LieberInstitute/brainseq_phase1
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No unique materials were used -sequencing data will be made available as described below 9. Antibodies Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). No animals were used
